Loading...
XSHG
600079
Market cap4.68bUSD
Oct 09, Last price  
19.23CNY
1D
0.26%
1Q
10.96%
Jan 2017
-3.61%
Name

Humanwell Healthcare Group Co Ltd

Chart & performance

D1W1MN
XSHG:600079 chart
P/E
16.92
P/S
1.31
EPS
1.14
Div yield, %
1.67%
Shrs. gr., 5y
3.30%
Rev. gr., 5y
2.99%
Revenues
23.96b
-5.79%
758,879,685705,060,0001,024,369,4641,330,209,2172,204,798,7993,598,111,5575,317,093,0086,010,211,3977,051,628,03710,053,978,40212,330,950,05215,445,684,00018,633,826,00021,806,605,80320,680,111,11320,548,930,20222,337,719,41624,524,740,57225,435,484,34923,962,010,000
Net income
1.86b
+39.53%
102,730,09869,440,55778,197,554201,472,882216,466,205300,354,201405,990,789417,780,080451,770,967653,823,537832,403,3912,068,720,000-2,357,747,000842,544,8951,005,733,4921,317,145,5492,484,108,5892,134,484,6941,329,744,9911,855,334,000
CFO
2.52b
+16.38%
84,437,97455,050,30934,969,189154,510,417111,386,11894,231,577172,273,069498,216,711502,704,784311,216,560526,477,79038,167,500602,993,6212,037,831,5531,988,506,2722,178,810,5202,441,071,0541,967,249,7252,164,265,0592,518,723,812
Dividend
Aug 03, 20260.48 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Humanwell Healthcare (Group) Co.,Ltd. operates internationally, delivering a wide spectrum of healthcare solutions across regions including the Asia Pacific, North America, and Africa. The company's diverse product range features pharmaceuticals for pain management, such as anesthetics and analgesics, alongside a significant focus on women's health, providing items for reproductive planning, emergency contraception, and general wellness. They also produce central nervous system (CNS) medications addressing conditions like bronchitis, migraines, dysmenorrhea, neuralgia, epilepsy, acute and chronic cerebrovascular diseases, brain injuries, and peripheral vascular disorders. Furthermore, their offerings extend to traditional herbal remedies for common ailments such as colds and flu, rheumatoid arthritis, dermatological concerns, hepatitis, urinary tract infections, and memory impairment. Humanwell also supplies anti-infective agents, a variety of over-the-counter (OTC) drugs for digestive complaints, cold and flu relief, anti-inflammatory purposes, infections, and nutritional supplements. Complementing these, they offer specific treatments aimed at cardiovascular, gastrointestinal, and reproductive system diseases. Established in Wuhan, China, in 1993, the enterprise was initially known as Wuhan Humanwell Healthcare (Group) Co., Ltd. before adopting its current name, Humanwell Healthcare (Group) Co.,Ltd., in March 2013.

Key people

Xue Hai Wang
Chairman of the Board · since 2006
Yajun Wu
Chief Financial Officer, Vice President
Wentao Du
Vice President
Qianlun Li
Vice President, Secretary of the Board · since 2013
Huabin Xu
Vice President
Lu Ming Ai
Director · since 2006
Xia Fei Deng
Vice President, Director
Xiaoling Fan
Director · since 2009
Jie Li
President, Director
Xiaodong Zhang
Director · since 2005
Independent Director · since 2008
IPO date
Jun 06, 1997
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
武汉东湖高新区高新大道666号
武汉市, HB 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT